Bio-Rad Laboratories (BIO) Cash from Financing Activities (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Cash from Financing Activities for 18 consecutive years, with -$44.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 54.96% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$229.5 million (up 27.49% YoY), while the FY2025 annual figure was -$283.2 million, down 29.43% from the prior year.
• Cash from Financing Activities eased to -$44.0 million in Q1 2026 per BIO's latest filing, from $3.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $1.2 billion in Q1 2022 and bottomed at -$202.7 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged $125000.0 across 5 years, with a median of -$69.5 million in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 2613.98% in 2022 and fell as far as 4334.76% in 2022.
• Bio-Rad Laboratories' Cash from Financing Activities stood at -$86.6 million in 2022, then slumped by 131.62% to -$200.6 million in 2023, then jumped by 86.94% to -$26.2 million in 2024, then jumped by 112.6% to $3.3 million in 2025, then plunged by 1433.33% to -$44.0 million in 2026.
• Business Quant data shows BIO's Cash from Financing Activities at -$44.0 million in Q1 2026, $3.3 million in Q4 2025, and -$52.5 million in Q3 2025.